Page 2 - Indian Pharma Companies

GMP, NSQ compliance: MSME pharmaceutical companies seek financial aid

Pharma MSMEs seek Rs 50 crore handholding and extension for GMP compliance under revised Schedule M, citing challenges in adhering to regulatory and quality standards

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous Injection

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

US govt order to have nil impact on Indian pharma players, says Cipla

The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian generic drugmakers, Cipla MD and Global CEO Umang Vohra said on Tuesday. He noted that the Executive Order signed by US President Donald Trump on Monday is probably going to impact branded drugs. "What we understand is that this is largely targeted towards branded drugs...As of now, what we understand is that this is a voluntary measure that perhaps the companies will be taking," Vohra stated. He noted that there are aspects of MFN clauses etc and it is not clear as of now how and in which manner the Executive Order will be implemented. "So as of now, from a generic perspective, I think generic (drug) prices in the US are already significantly comparable with the rest of the world, in some cases it is lower. So we don't believe that at least for now, based on what the promulgation says we think this is more (towards) branded sector...rather anything on the ...

Dr Reddy's: Brokerage reports by JM Financial, Motilal Oswal as stock up 4%

DRL's management has guided for double-digit growth in FY26, with margins expected to remain similar to FY25 levels. Here's what brokerages expect from the company going ahead

Schedule M rollout may face delay as MSMEs seek more time for upgrade

Small drugmakers seek a three-month extension to submit GMP compliance plans under revised Schedule M, raising concerns about delays in national rollout

Trump targets foreign drugs: Tariffs in 2 weeks, begins US mfg push

US President Trump has signed executive orders to speed up drug approvals and pharma infrastructure construction in the US

Pharma shares slide up to 10% as Trump to announce pharma tariffs 'soon'

Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%

Short-term painkiller? Pharma Inc gets a breather from US tariffs

Tariff worries, raw material costs still ail sector

'Scenario building' in Indian Pharma Inc ahead of US tariff announcement

Pharmaceutical products have been on the radar of US President Donald Trump, who has indicated that tariffs of up to 25 per cent could be imposed on this category

Will US tariffs succeed in lifting the veil on India's drug safety problem?

Over 30 per cent of Indian pharma exports go to the US, and it provides an even larger proportion of earnings

CDSCO asks MSME pharma firms to apply online for Schedule M extension

This comes after the health ministry had on February 11 formally extended the deadline for implementing the revised Schedule M by one year for pharma companies with an annual turnover below Rs 250 cr

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

India's pharma exports set for 10x growth, targeting $350 billion by 2047

Indian biosimilar exports, presently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and reach $30-35 billion by 2047

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Small, medium-sized pharma firms gear up to comply with revised Schedule M

Pharma groups had wanted two year extension, will raise concerns with govt

Indian pharma improves compliance with USFDA; fewer OAI cases in 2024

Recent USFDA data reveals a decline in the number of adverse classification outcomes of inspections